Find Academic Supervisors

Liam MannionView profile

Senior Lecturer

• Radiobiology
• Therapeutic Radiography
• Oncology
• +7 more

Dr. Liam Mannion is a Senior Lecturer in Therapeutic Radiography and Oncology at City St George’s, University of London, where he leads key modules in radiotherapy techniques, oncology, and radiobiology. He is an HCPC-registered Therapeutic Radiographer with clinical experience in both NHS and private sectors. He also serves as the Practice Education Lead for Therapeutic Radiography and is a Senior Fellow of the Higher Education Academy. PhD, King's College London MSc, London South Bank University PGCert, City, University of London BSc (Hons), University College Dublin His research focuses on optimizing treatments for muscle-invasive bladder cancer, patient-centered care, and radiobiology. He employs methodologies such as discrete choice experiments to understand patient preferences in treatment decisions. His educational interests include gamification, debriefing, and student well-being in radiography training. His recent publications reveal a strong trend in patient-centered oncology research, particularly in bladder cancer decision-making, alongside innovations in radiotherapy education. He frequently collaborates with institutions like King's College London and Guy's and St Thomas' NHS Foundation Trust. Dr. Mannion is actively involved in peer review for the Journal of Radiotherapy in Practice and served as an External Examiner at Cardiff University. He has also held leadership roles such as Joint Programme Director at City, University of London. He has contributed to research on compassion fatigue among students, leadership in radiography during the pandemic, and functional imaging in glioblastoma. His work bridges clinical practice, education, and patient-centered outcomes. Dr. Mannion is affiliated with professional organizations including the Health and Care Professions Council (HCPC) and the Society of Radiographers. He teaches across undergraduate modules in radiotherapy and oncology, with a focus on practical and theoretical integration.

James Ashton-MillerView profile

Professor

• Biomechanics
• ACL injury
• Sports injury
• +15 more

Dr. James Ashton-Miller is a prominent faculty member in the Department of Mechanical Engineering at the University of Michigan, where he directs the Biomechanics Research Laboratory. He serves as a Center Member of the University of Michigan Injury Prevention Center and maintains affiliations with the Institute of Gerontology. His interdisciplinary work bridges engineering principles with medical applications, focusing on injury prevention across sports medicine, obstetrics, and geriatrics. Dr. Ashton-Miller's educational background includes: PhD from the University of Oslo, Oslo, Norway (1978-1983) MSME from M.I.T., Cambridge, MA, U.S.A (1972-1974) B.SC. (Hons) from the University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, England (1967-1972) His research focuses on the biomechanics of injury prevention across multiple critical domains. In sports medicine, he has demonstrated that some ACL injuries are overuse injuries resulting from too many sub-maximal loading cycles that prevent healing of collagen damage. In women's health, his work on childbirth injuries addresses conditions that affect more women than breast cancer. His research on fall-related injuries in older adults reveals the dual threat of physical and cognitive factors. He also investigates sciatica, disc degeneration, and develops new medical devices for screening, diagnosis and treatment. Dr. Ashton-Miller's recent publications show a strong trend toward developing practical clinical applications from fundamental biomechanical research, with emphasis on advanced imaging methods, wearable sensors, and computational modeling for pelvic floor function assessment. His work consistently aims to translate engineering insights into clinical solutions for injury prevention. His research insights have earned him numerous national and international research awards, though specific awards aren't detailed in the available information. His work involves close collaboration with clinicians and surgeons who meet weekly to discuss progress and next steps. Dr. Ashton-Miller is deeply committed to mentoring, working with NIH K-series fellows along with 1-2 post-doctoral fellows, 3-5 PhD students, 2-4 M.S. students, 4-5 undergraduate students, and 2-4 young clinicians. His research is generously supported by the National Institutes of Health, National Science Foundation, National Basketball Association, Fortune 500 companies, and startup companies including Procter & Gamble and Hologic, Inc. He directs the Biomechanics Research Laboratory and co-leads the Pelvic Floor Research Group, where his teams develop new medical devices to improve screening, diagnosis, and treatment of various biomechanical conditions. These laboratories maintain strong clinical connections, ensuring research remains grounded in real-world medical challenges.

Ananya ChoudhuryView profile

Professor

• Radiation Therapy
• Prostate Cancer
• Bladder Cancer
• +9 more

Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.

Joshua WarrickView profile

Professor

• Bladder Cancer
• Carcinogenesis
• Urothelial Carcinoma
• +5 more

Joshua Warrick, MD is a Professor in the Department of Pathology and Laboratory Medicine and the Department of Urology at Pennsylvania State University College of Medicine. He serves as Chief of the Division of Anatomic Pathology. His research focuses on bladder cancer, carcinogenesis mechanisms, and molecular subtypes of urothelial tumors. Dr. Warrick has authored over 87 publications and led the National Cancer Institute-funded project on transcription factors in bladder cancer. Education: Medical Degree from Wayne State University (2007), followed by residencies in Internal Medicine (2008), Pathology (2009-2012), and a fellowship in Surgical & Genitourinary Pathology at the University of Michigan (2014). Research interests include bladder cancer pathogenesis, squamous differentiation in prostate cancer, and improving diagnostic standards for urothelial carcinomas. He received the 'Outstanding Collaborative Research Team' award in 2020 for multidisciplinary work in oncology. Advising and grants: Led a 2021-2023 NCI-funded project investigating transcription factors in non-invasive bladder cancer, with a focus on aggressive tumor phenotypes. Collaborates internationally on grading systems and diagnostic reproducibility in urologic pathology. Labs and teams: Active in the Penn State Cancer Institute’s 'Mechanisms of Carcinogenesis' unit, leveraging anatomic pathology expertise to advance translational oncology research.

Ian DavisView profile

Professor

• Cancer Immunology
• Urologic Cancers
• Oncology
• +4 more

Professor Ian Davis is a medical oncologist and holds the position of Professor of Medicine and Head of the Eastern Health Clinical School at Monash University in Melbourne, Australia. He also serves as an Affiliate Professor at Deakin University, adjunct Associate Professor at the University of Melbourne, and holds roles at The George Institute and the University of New South Wales. His primary clinical focus is on urologic cancers, with research interests in cancer immunology and the biology of urologic malignancies. He completed his MBBS (First Class Honours) at Monash University (1983) and a PhD in Cancer Immunology from the University of Melbourne (1997). Davis has published over 300 papers, attracted $30M+ in grants, and led over 200 clinical trials as Principal Investigator. His research emphasizes genitourinary cancers, including bladder, renal, and prostate cancers. Recent projects include studies on PSMA-targeted therapies, immunotherapy combinations, and clinical trial design in metastatic prostate cancer. Davis chairs the ANZUP Cancer Trials Group, overseeing its Scientific Advisory Committee. Key Awards: NHMRC Leadership Fellow L3 (2023-2027) Grants & Collaborations: Over $30M in funding, including NHMRC grants and industry partnerships His articles highlight advances in targeted therapies, biomarker validation, and clinical trial innovations, with a focus on improving patient outcomes in metastatic cancers.

• Radiation Oncology
• Gastrointestinal Cancers
• Head and Neck Cancers
• +3 more

Shane Lloyd, MD, is an Associate Professor in the Department of Radiation Oncology at the University of Utah School of Medicine, affiliated with Huntsman Cancer Institute. He specializes in treating gastrointestinal, head/neck, and genitourinary cancers. His research emphasizes improving care quality through data analysis, clinical trials, and addressing health disparities in cancer survivorship. Education: M.D. & M.H.S. from Yale School of Medicine B.A. in Economics and Zoology from Brigham Young University Residency in Radiation Oncology at Yale New Haven Hospital Internship at University of Utah Affiliated Hospitals Research Focus: Dr. Lloyd investigates radiation therapy optimization, cancer survivorship outcomes, and socio-geographic health disparities. His work integrates population-based data analytics to evaluate treatment efficacy, mental health impacts, and equitable care access. Publications: Recent articles (2022–2025) highlight trends in prostate, bladder, and gastrointestinal oncology, with emphasis on immunotherapy combinations, survivorship disparities, and biomarker-driven recurrence detection. Machine learning applications in treatment decision-making and rural health inequities are recurring themes. Leadership: Chairs the Radiological Drug Research Committee (RDRC) and Human Use Subcommittee of the Radiation Safety Committee (HUS-RSC).

Sara E. WobkerView profile

Associate Professor

• Genitourinary Pathology
• Molecular Characterization of Cancers
• Bladder Cancer Research
• +3 more

Sara E. Wobker, MD, MPH, is an Associate Professor in both the Department of Pathology and Laboratory Medicine and the Department of Urology at the University of North Carolina at Chapel Hill . She also serves as Director of Anatomic Pathology , Director of Genitourinary Pathology , and Director of Surgical Pathology . Her research focuses on genitourinary malignancies , particularly the molecular characterization of rare variants of bladder carcinoma . She aims to translate histologic findings into molecular discoveries to improve patient care, with a recent emphasis on tumor microenvironment dynamics and immunotherapy response mechanisms in muscle-invasive bladder cancer. Analysis of her 15 most recent articles (2024-2021) reveals a strong trend in immunotherapy response , molecular subtyping , and diagnostic standardization for genitourinary cancers. Key subfields include FGFR inhibition , TFE3 gene fusions , clinicogenomic features , and pathology protocol optimization . Scientific Awards UNC Junior Faculty Development Award (2018-2019) As Faculty Director of the Pathology Services Core, she supports clinical trials , translational studies , and basic science research . She collaborates extensively with interdisciplinary teams in the UNC Lineberger Comprehensive Cancer Center, contributing to updates in renal and prostate cancer grading through the Genitourinary Pathology Society (GUPS).

Chi TangView profile

Associate Professor

• Energy Engineering Technologies
• Health Technology
• Industry 4.0
• +3 more

Dr. Chi Tang is a retired Associate Professor at the W Booth School of Engineering Practice and Technology, McMaster University. His expertise spans Energy Engineering Technologies, Health Technology, Industry 4.0, and Sustainable Infrastructure. He specializes in Digital & Smart Systems and Energy research clusters. Dr. Tang taught courses such as ENRTECH 3EP3 (Electrical Power Generation), ENRTECH 4PD3 (Power System Analysis and Control), and others focused on power systems, protection, and maintenance. His research interests include transient stability analysis, energy margin calculations, and applications of energy functions in power systems. His scholarly contributions include studies on oncology treatments (e.g., pembrolizumab combinations) and foundational work in power system dynamics. Despite retirement, his legacy persists through his academic contributions and course development in power engineering technology.

Stephen RamseyView profile

Associate Professor

• Computational Systems Biology
• Bioinformatics
• Precision Medicine
• +6 more

Stephen Ramsey, an Associate Professor at Oregon State University, holds dual appointments in the School of Electrical Engineering and Computer Science (College of Engineering) and the Department of Biomedical Sciences (Carlson College of Veterinary Medicine). With a PhD in Physics from the University of Maryland, his postdoctoral training in computational genomics at the University of Washington, and professional experience at the Institute for Systems Biology and Center for Infectious Disease Research, Ramsey bridges computational methods with biomedical applications. Education : Ph.D., Physics, University of Maryland; M.S., Physics, University of Maryland; Sc.B., Mathematical Physics, Brown University Ramsey specializes in computational systems biology , focusing on bioinformatics , biomedical knowledge graphs , and precision medicine . His research integrates machine learning , gene regulatory network modeling , and multi-omics data analysis to address challenges in rare disease diagnostics , drug monitoring , and inflammatory disease mechanisms . Current work includes AI-driven biomedical translation and electrochemical biosensor development for non-invasive diagnostics . Recent publications highlight knowledge graph applications in translational biomedicine , causal network inference in clinical-environmental data integration , and cross-species cancer transcriptomics . His team develops tools like RTX-KG2 and PloverDB to standardize biomedical data sharing and semantic reasoning . Scientific Awards : 2019 Zoetis Award (Carlson College of Veterinary Medicine) 2016 NSF CAREER Award 2016 PhRMA New Investigator Award 2010 NIH K25 Mentored Quantitative Research Award Ramsey advises in computational biology courses (CS 446/546) and contributes to biomedical AI through projects like mediKanren for rare disease diagnostics . His NSF-funded research explores gene expression noise and regulatory network dynamics , while NIH and PhRMA grants support his translational medicine initiatives. He leads the Ramsey Laboratory , which develops graph-based reasoning tools for biomedical data translation and multi-omics integration . The lab's work spans comparative oncology models, electrochemical biosensors , and knowledge graph infrastructure for clinical decision support .

Kevin J. WuView profile

Physician Scientist

• Pathology
• Oncology
• Urology
• +3 more

Kevin J. Wu, M.D., is a pathologist at the Mayo Clinic College of Medicine and Science, Jacksonville, Florida. His work spans oncology , urologic pathology , and molecular mechanisms of cancer . Education : MD, University of Arkansas for Medical Sciences (1994); BA, Psychology, University of Arkansas (1990). Dr. Wu's research focuses on renal cell carcinoma , prostate cancer , and urologic tumors , with an emphasis on biomarker discovery and imaging correlations . His publications highlight collaborations in multidisciplinary cancer research and post-treatment complications . Recent articles explore topics such as pancreatic hemangioblastoma in tuberous sclerosis (2024), radiation therapy outcomes in prostate cancer (2023), and molecular targets in renal cell carcinoma (2013). His work has appeared in journals like Clinical Cancer Research , Urologic Oncology , and Mayo Clinic Proceedings . Scientific Awards : Above and Beyond Mayo Clinic Award (2006); Alpha Omega Alpha Honor Medical Society (since 1994). Dr. Wu is actively involved in Digital Pathology initiatives at Mayo Clinic and has served on committees related to clinical equipment and urologic oncology . His expertise combines anatomic pathology , molecular diagnostics , and translational cancer research .

Firas AljaberyView profile

Adjunct Assistant Professor

• Urology
• Oncology
• Bladder Cancer
• +5 more

Firas Aljabery serves as an Adjunct Assistant Professor at Linköping University, holding dual appointments in the Department of Surgery, Orthopaedics and Oncology (KOO) and the Department of Biomedical and Clinical Sciences (BKV). His academic profile centers on clinical urology and oncology research with emphasis on bladder cancer epidemiology and translational studies leveraging Sweden's national healthcare registries. Dr. Aljabery's research program addresses critical gaps in bladder cancer management through five key domains: gender-based survival disparities following radical cystectomy, multidisciplinary team referral optimization using the MeDiC score, secondary cancer risk assessment after non-muscle-invasive disease, national clinical guideline development for advanced urothelial carcinoma, and urinary biomarker validation for malignancy stratification. His work consistently utilizes population-based cohort methodologies with nationwide Swedish datasets to generate evidence for clinical decision-making. Analysis of his 2025 publications reveals a cohesive research trajectory focused on improving bladder cancer outcomes through system-level interventions and molecular diagnostics. These studies demonstrate strong alignment with national guideline committees and cancer registry initiatives, emphasizing real-world applicability of findings for urologic oncology practice. The collaborative nature of his work spans multiple Swedish institutions and clinical specialties. No scientific awards or honors were documented in the source materials. While specific grant funding and student supervision details were not provided, his involvement in nationwide population studies and guideline committees indicates participation in significant collaborative research initiatives. The publication patterns suggest engagement with both clinical urology teams and translational research groups. Dr. Aljabery's work positions him within Sweden's national urologic cancer research infrastructure, particularly through contributions to the Swedish National Guidelines group for urothelial carcinoma. His dual departmental affiliations reflect integration between surgical oncology (KOO) and translational biomedical research (BKV) environments at Linköping University.

• Cancer and Oncology
• Surgery
• Urology
• +3 more

Professor Peter Wiklund is a Senior Physician and academic at Karolinska Institutet, affiliated with the Department of Molecular Medicine and Surgery. His research focuses on urological oncology, particularly prostate and bladder cancers, with a strong emphasis on surgical innovations like robotic-assisted procedures and molecular diagnostics. He leads the Urology research group within Olof Akre's team, contributing to advancements in precision medicine and surgical outcomes. Research interests include robotic surgery outcomes for radical cystectomy and prostatectomy, biomarker development (e.g., circulating tumor DNA), and optimizing therapies for non-muscle-invasive bladder cancer. His work spans clinical trials and translational research, addressing complications, oncological efficacy, and patient quality of life. Recent publications highlight advancements in robotic surgical techniques, biomarker utilization, and comparative efficacy of treatments like BCG vs. chemotherapy regimens. His contributions span high-impact journals such as *European Urology*, *BJU International*, and *World Journal of Urology*.

Francisco Emilio Vera-BadilloView profile

Associate Professor

• Clinical Oncology
• Cancer Clinical Trials
• Prognostic Biomarkers
• +4 more

Dr. Francisco Emilio Vera-Badillo is an Associate Professor at Queen's University and a Regular Attending Staff in Medical Oncology at Kingston General Hospital. He leads the Canadian Cancer Trials Group's Thoracic and Genito-urinary malignancies team. His clinical expertise spans Genitourinary, Lung, and Breast Cancers, with a focus on clinical trials and meta-analyses evaluating prognostic markers and treatment efficacy. Education: MD: School of Medicine Ignacio A. Santos, Monterrey Institute of Technology and Higher Education, 2003 Internal Medicine: Hospital San Jose – TEC de Monterrey, 2008 Medical Oncology: Centro Universitario Contra el Cancer, Autonomous University of Nuevo Leon, 2011 MSc: Institute of Medical Science, University of Toronto, 2014 Research Focus: Clinical trials design, biomarker-driven therapies, and outcomes analysis in oncology, particularly in prostate, bladder, and lung cancers. His research emphasizes translational applications of biomarkers (e.g., ctDNA, NECTIN4) and novel therapeutic combinations (e.g., immunotherapy, PARP inhibitors). Recent work includes evaluating cannabinoids' impact on checkpoint inhibitors and assessing real-world treatment patterns in metastatic cancers. Dr. Vera-Badillo’s contributions include leadership in cooperative trials like the ENZAMET phase III study and the CCTG IND.234 ctDNA-directed trial. He advocates for methodological rigor in clinical research and addresses disparities in healthcare access, particularly in Latin America.

• Cancer Stem Cells
• Tumor Microenvironment
• Precision Medicine
• +7 more

Giorgio Stassi serves as a Professor in the Department of Surgical and Oncological Disciplines at the School of Medicine and Surgery , University of Palermo . His research focuses on cancer stem cells (CSCs) across colorectal, breast, and thyroid malignancies, with emphasis on microenvironment interactions and therapy resistance mechanisms. Office hours are held weekly at the Laboratory of Cellular and Molecular Pathophysiology in Palermo. His research interests include: Precision Medicine applications in CSC-targeted therapies Immunological profiling of tumor microenvironments Epigenetic and metabolic drivers of chemoresistance Bioinformatic analysis of CSC phenotypes Drug repurposing for CSC eradication Recent publications demonstrate a clear trend toward computational oncology and immunomicroenvironment engineering , with notable work on tumor-on-chip systems, NGS-based prognostics, and macrophage-CSC crosstalk. Key journals include Magazine article and Review essay formats addressing clinical translation of laboratory findings. No scientific awards were documented in the provided materials. His supervisory activities include thesis guidance ("Tesi curate") and Erasmus program coordination, though specific students and projects aren't listed. Research is conducted primarily at the Laboratory of Cellular and Molecular Pathophysiology , with institutional support from the ATeN Center and ASCENT Advanced Studies Centre.

Ahmed AboumohamedView profile

Professor

• Urologic Oncology
• Minimally Invasive Surgery
• Robotic Surgery
• +4 more

Ahmed Aboumohamed, MD, serves as Professor in the Department of Urology at Albert Einstein College of Medicine and Attending Physician at Montefiore Medical Center in Bronx, NY. His clinical practice specializes in urologic oncology, minimally invasive robotic surgery, and complex urologic reconstruction, with particular expertise in high-risk prostate cancer and bladder cancer management using advanced surgical techniques. Dr. Aboumohamed's academic training includes: Medical degree (M.B., B.Ch.), clinical masters, and clinical doctorate in urology from Cairo University School of Medicine Urology residency at Cairo University Hospital Fellowships at Cleveland Clinic, Roswell Park Cancer Institute, Wake Forest University Baptist Medical Center, and Montefiore Medical Center His research program focuses on three primary domains: (1) minimally invasive approaches for urologic cancers, particularly robotic-assisted radical prostatectomy and cystectomy; (2) the relationship between microbiome composition and prostate/bladder cancer development; and (3) innovative techniques for complex urethral reconstruction in post-transplant and oncologic patients. He actively investigates surgical optimization for high-risk cases and novel applications of robotic platforms. Analysis of his 2016-2021 publications reveals concentrated research on robotic surgical outcomes, with significant contributions to radical cystectomy techniques, prostate biopsy methodologies, and bladder cancer immunotherapy. His work demonstrates consistent multi-institutional collaboration, particularly through the International Robotic Cystectomy Consortium, and addresses critical gaps in quality-of-life metrics, perioperative outcomes, and rare urologic conditions including urethral melanoma and renoduodenal fistulas. Dr. Aboumohamed maintains active professional engagement through memberships in the European Association of Urology (EAU) and American Urological Association (AUA), contributing to clinical guideline development and scholarly discourse in urologic oncology.